PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

CDIB Capital Group

TaipeiCDIB-CAPITAL-GROUP
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

No summary available yet.

Classification
Slugcdib-capital-group
HQTaipei
Stage FocusMulti-stage investor from early (Series A/B) to buyout, w…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

CDIB is Taiwan's legacy PE giant trying to evolve into a modern institutional player - think of them as the KKR of Taiwan, but with more government ties and less global polish. William Ho's CVC pedigree is legit and they've got serious capital ($25B+ AUM), but this is fundamentally a relationship-driven, Taiwan-centric shop that happens to have some Silicon Valley exposure. The 'China Plus' strategy sounds fancy but really means 'help Taiwanese companies expand to China and vice versa.' They're conservative, well-connected in Asia, and have genuine operational expertise in traditional industries, but don't expect the cutting-edge thesis or hands-on value creation you'd get from top-tier US funds. If you're building in hardware, manufacturing, or need Asia expansion, they're solid. If you're doing pure software or need Silicon Valley connections, look elsewhere.

KEY TAKEAWAYS
  • Best for: Asia expansion, hardware/manufacturing, traditional industries
  • Watch out for: Conservative pace, relationship-heavy processes, limited US networks
  • Known for: Taiwan's largest PE firm, strong government/corporate connections, patient capital
Investment Thesis

CDIB Capital Group focuses on cross-border Asia-Pacific investments with their 'China Plus' strategy, targeting growth companies that can benefit from cross-fertilization between China and closely linked regional economies. They deploy capital through multiple platforms covering venture, growth, buyout, and private credit opportunities.

Stage & Sector Focus

Multi-stage investor from early (Series A/B) to buyout, with particularly strong focus on life sciences (27 investments), high tech/semiconductors (14), healthcare, and traditional manufacturing. Heavy Taiwan/Greater China geographic focus with US expansion.

Notable Portfolio
FacebookGogoroJD.comRokidFractyl HealthAlar PharmaceuticalsxMEMSAutozi
Key Partners
William Ho
President

Former CVC Asia Pacific managing partner who raised over $10B and completed 100+ deals across tech, retail, education, healthcare and industrials. 25+ years PE experience, UBC MBA. The heavy-hitter fundraiser and deal maker driving CDIB's institutional expansion.

Melanie Nan
Senior Executive Vice President

Former General Counsel for parent company China Development Financial (CDF). Legal background turned PE executive, now helping lead CDIB's institutional strategy and fund launches including recent NexGen Partners success.

Alex Ying
Head of Buyout Group

Leads CDIB NexGen Partners, the dedicated buyout platform focusing on mid-market opportunities in Greater China. Recently closed continuation fund with StepStone and other global institutionals backing his team's strategy.

Have a specific question about CDIB Capital Group?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1